RU94045798A - Стереоизомеры итраконазола или саперконазола, способ их получения, их комплексы и способ получения, фармацевтическая композиция на их основе и ее получение, способ получения водных растворов с повышенной концентрацией итраконазола или саперконазола - Google Patents

Стереоизомеры итраконазола или саперконазола, способ их получения, их комплексы и способ получения, фармацевтическая композиция на их основе и ее получение, способ получения водных растворов с повышенной концентрацией итраконазола или саперконазола

Info

Publication number
RU94045798A
RU94045798A RU94045798/04A RU94045798A RU94045798A RU 94045798 A RU94045798 A RU 94045798A RU 94045798/04 A RU94045798/04 A RU 94045798/04A RU 94045798 A RU94045798 A RU 94045798A RU 94045798 A RU94045798 A RU 94045798A
Authority
RU
Russia
Prior art keywords
preparing
saperconazole
itraconazole
complexes
synthesis
Prior art date
Application number
RU94045798/04A
Other languages
English (en)
Other versions
RU2127733C1 (ru
Inventor
Херес Жан
Nl]
Луи Мезен Жан
Петер Жозеф
Be]
Original Assignee
Жансен Фармасетика Н.В. (BE)
Жансен Фармасетика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25316567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU94045798(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Жансен Фармасетика Н.В. (BE), Жансен Фармасетика Н.В. filed Critical Жансен Фармасетика Н.В. (BE)
Publication of RU94045798A publication Critical patent/RU94045798A/ru
Application granted granted Critical
Publication of RU2127733C1 publication Critical patent/RU2127733C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к стереоизомерным формам итраконазола (X=С1) и саперконазола (X= F), которые могут быть представлены формулой цис-(1), их фармацевтически приемлемым кислотно-аддитивным солевым формам, способам получения указанных стереоизомерных форм, их комплексам с производными циклодекстрина, фармацевтическим композициям, содержащим указанные комплексы, и к способам получения указанных комплексов и фармацевтических композиций.

Claims (1)

  1. Изобретение относится к стереоизомерным формам итраконазола (X=С1) и саперконазола (X= F), которые могут быть представлены формулой цис-(1), их фармацевтически приемлемым кислотно-аддитивным солевым формам, способам получения указанных стереоизомерных форм, их комплексам с производными циклодекстрина, фармацевтическим композициям, содержащим указанные комплексы, и к способам получения указанных комплексов и фармацевтических композиций.
RU94045798A 1992-03-18 1993-03-10 Стереоизомеры итраконазола или саперконазола, способ их получения, их комплексы и фармацевтическая композиция на их основе RU2127733C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85364892A 1992-03-18 1992-03-18
US853648 1992-03-18
PCT/EP1993/000552 WO1993019061A1 (en) 1992-03-18 1993-03-10 Itraconazole and saperconazole stereoisomers

Publications (2)

Publication Number Publication Date
RU94045798A true RU94045798A (ru) 1996-07-20
RU2127733C1 RU2127733C1 (ru) 1999-03-20

Family

ID=25316567

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94045798A RU2127733C1 (ru) 1992-03-18 1993-03-10 Стереоизомеры итраконазола или саперконазола, способ их получения, их комплексы и фармацевтическая композиция на их основе

Country Status (22)

Country Link
US (1) US5998413A (ru)
EP (1) EP0631578B1 (ru)
KR (1) KR100243534B1 (ru)
AT (1) ATE201408T1 (ru)
AU (1) AU665988B2 (ru)
CA (1) CA2117651C (ru)
CZ (1) CZ286619B6 (ru)
DE (1) DE69330248T2 (ru)
DK (1) DK0631578T3 (ru)
ES (1) ES2158859T3 (ru)
FI (1) FI113175B (ru)
GR (1) GR3036368T3 (ru)
HK (1) HK1010729A1 (ru)
HU (1) HU221189B1 (ru)
NO (1) NO307786B1 (ru)
NZ (1) NZ249494A (ru)
PL (1) PL172358B1 (ru)
PT (1) PT631578E (ru)
RU (1) RU2127733C1 (ru)
SK (1) SK283118B6 (ru)
WO (1) WO1993019061A1 (ru)
ZA (1) ZA931906B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016700A1 (en) * 1993-01-27 1994-08-04 Sepracor, Inc. Method and composition employing (2r,4s) itraconazole
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
US5486625A (en) * 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
ES2112151B1 (es) * 1995-03-17 1999-09-16 Menarini Lab Nuevos compuestos homoquirales para la preparacion de ketoconazol, terconazol y antifungicos relacionados, procedimiento para su fabricacion y utilizacion de los mismos.
WO1997039761A1 (en) 1996-04-19 1997-10-30 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
EP0904060B1 (en) * 1996-05-20 2003-12-10 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
AU5251398A (en) * 1996-11-12 1998-06-03 Sepracor, Inc. (2r,4s,r,r-) and (2s,4r,r,r-)hydroxyitraconazole
EP0942725A1 (en) * 1996-11-12 1999-09-22 Sepracor, Inc. Use of cis-hydroxyitraconazole in order to avoid side-effects of itraconazole and hydroxyintraconazole
US5952502A (en) * 1996-11-12 1999-09-14 Sepracor Inc. 2R,4S,R, S- and 2S,4R,R,S-hydroxyitraconazole
WO1998021203A1 (en) * 1996-11-12 1998-05-22 Sepracor, Inc. 2r,4s,s,r- and 2s,4r,s,r-hydroxyitraconazole
CN1102592C (zh) * 1996-11-12 2003-03-05 塞普拉科公司 2r,4s,s,s－和2s,4r,s,s－羟基伊曲康唑
ES2224364T3 (es) 1997-02-11 2005-03-01 Janssen Pharmaceutica N.V. Azoles antifungicos que contienen esteres de aminoacidos.
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
EP0957101A1 (en) * 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
DE60023465T2 (de) 1999-03-24 2006-07-20 R.P. Scherer Technologies, Inc., Las Vegas Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7078526B2 (en) * 2002-05-31 2006-07-18 Transform Pharmaceuticals, Inc. CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
IL165383A0 (en) 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
KR100446256B1 (ko) * 2002-07-11 2004-09-01 경동제약 주식회사 고 광학선택성을 가지는시스-2-(브로모메틸)-2-(2,4-디클로로페닐)-13-디옥소란-4-메틸알콜의 제조방법
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20090028938A1 (en) 2005-08-08 2009-01-29 Abbott Gmbh & Co. Kg Dosage forms with improved bioavailability
US8486456B2 (en) 2005-08-08 2013-07-16 Abbott Gmbh & Co., Kg Itraconazole compositions with improved bioavailability
EP1919480B1 (en) 2005-08-22 2013-01-16 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
US9072660B2 (en) 2011-09-09 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Topical itraconazole formulations and uses thereof
CN102379844A (zh) * 2011-10-31 2012-03-21 广州维美投资有限公司 一种伊曲康唑异构体注射剂
CN105061411A (zh) * 2015-06-23 2015-11-18 扬州艾迪生物科技有限公司 一种光学异构体2s,4r,2’s-伊曲康唑晶型及制备方法与应用
CN106146480B (zh) * 2016-07-18 2019-08-06 山东罗欣药业集团恒欣药业有限公司 一种伊曲康唑的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4490530A (en) * 1981-01-14 1984-12-25 Janssen Pharmaceutica N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)-methyl-1H-imidazoles and 1H-1,2,4-triazoles
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
FR2622198B1 (fr) * 1987-10-21 1992-04-30 Mero Rousselot Satia Compositions granulees de polysaccharides a dissolution aqueuse instantanee, procede pour leur preparation et utilisation
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
US5214046A (en) * 1989-07-27 1993-05-25 Hoffmann-La Roche Inc. Substituted aminoalkoxybenzene anti-fungicidal compositions and use
WO1994016700A1 (en) * 1993-01-27 1994-08-04 Sepracor, Inc. Method and composition employing (2r,4s) itraconazole

Also Published As

Publication number Publication date
HU9402656D0 (en) 1994-11-28
DK0631578T3 (da) 2001-08-27
NO943450L (no) 1994-11-11
KR950700904A (ko) 1995-02-20
HUT71835A (en) 1996-02-28
SK283118B6 (sk) 2003-02-04
PT631578E (pt) 2001-11-30
FI113175B (fi) 2004-03-15
ES2158859T3 (es) 2001-09-16
SK110694A3 (en) 1995-04-12
HK1010729A1 (en) 1999-06-25
FI944311A0 (fi) 1994-09-16
EP0631578B1 (en) 2001-05-23
NO307786B1 (no) 2000-05-29
PL172358B1 (en) 1997-09-30
ZA931906B (en) 1994-09-17
DE69330248D1 (de) 2001-06-28
DE69330248T2 (de) 2002-03-21
ATE201408T1 (de) 2001-06-15
NO943450D0 (no) 1994-09-16
CA2117651C (en) 2006-01-03
NZ249494A (en) 1996-04-26
AU665988B2 (en) 1996-01-25
HU221189B1 (en) 2002-08-28
RU2127733C1 (ru) 1999-03-20
AU3632493A (en) 1993-10-21
GR3036368T3 (en) 2001-11-30
WO1993019061A1 (en) 1993-09-30
KR100243534B1 (ko) 2000-03-02
US5998413A (en) 1999-12-07
CA2117651A1 (en) 1993-09-30
CZ286619B6 (cs) 2000-05-17
CZ221594A3 (en) 1995-01-18
EP0631578A1 (en) 1995-01-04
FI944311A (fi) 1994-09-16

Similar Documents

Publication Publication Date Title
RU94045798A (ru) Стереоизомеры итраконазола или саперконазола, способ их получения, их комплексы и способ получения, фармацевтическая композиция на их основе и ее получение, способ получения водных растворов с повышенной концентрацией итраконазола или саперконазола
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
FI98460B (fi) Menetelmä terapeuttisesti käyttökelpoisen 4H-1-bentsopyran-4-onijohdoksen tai sen suolan valmistamiseksi ja menetelmässä käyttökelpoinen välituote
RU94038064A (ru) Производные пиперазина и пиперидина, их применение в качестве противопсихотических средств, способ их получения фармацевтическая композиция
YU149791A (sh) Mometason, furoat monohidrat i postupak za njegovo dobijanje
ATE45580T1 (de) 9-(2-hydroxyethoxymethyl)guanin-derivate.
RU93004793A (ru) Производные хиназолина, способ их получения, фармацевтическая композиция на их основе
FR2361901A1 (fr) Derives de substitution de nucleotides et medicament contenant ces substances
FI940696A (fi) Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö
RU94036749A (ru) Замещенные 1-нафтилпиразол-3-карбоксамиды, способ их получения, содержащие их фармацевтические композиции и промежуточные соединения синтеза
RU95105977A (ru) Комплексы включения солей нимезулида с циклодекстринами, способ их получения, фармацевтические композиции на их основе и способ лечения
DE179430T1 (de) Waessrige arzneiformulierungen des piroxicammonohydrats.
NO922901D0 (no) Pleuromutilinderivater, fremgangsmaate for deres fremstilling og farmasoeytiske preparater omfattende de nevnte derivater
DE69330601T2 (de) Serotoninergische ergolin derivate
UA27242C2 (uk) Комплекс включення 3-морфоліносидноніміну, або його солей, або його таутомірного ізомеру, що має антиішемічний ефект, спосіб їх отримання, фармацевтична композиція, спосіб її одержання та спосіб лікування ішемічної хвороби серця
RU94046058A (ru) Агент для лечения и профилактики катаракты, способ его получения, применение (+) - (2s, 3s)-3 (s)-3-метил-1-(3-метилбутилкарбомоил)бутилкарбамоил]-2-оксикарбоновой кислоты ее соли и ее этилового эфира для получения агента, способ лечения и профилактики катаракты, способ получения водного раствора
ATE141612T1 (de) Conalbumin und seine derivate enthaltende eisenkomplexe
KR930023338A (ko) 데포우 제제
RU93051781A (ru) Бета -фенилизосерин-(2r,3s) и его соли, способ его получения и его применения
KR890007731A (ko) 생물학적으로 매우 유용한 형태의 철을 함유한 단백질 유도체, 그의 제조 및 이 화합물을 함유하는 제약 조성물
AU621677B2 (en) Stable aqueous solutions of primycin, pharmaceutical and cosmetic compositions containing these solutions and process for preparing same
DE1012607B (de) Verfahren zur Herstellung von wasserloeslichen therapeutischen Mitteln mit baktericider bis bakteriostatischer Wirkung
RU94042399A (ru) Получения клавулановой кислоты из соли клавулановой кислоты и амина, соли клавулановой кислоты и амина
FR2373539A1 (fr) Derives de l'acide dithiocarbamique, leur procede de preparation et leur application en medecine veterinaire
GB1255591A (en) Compositions for use as eye drops or eye lotion

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080311